Drugs /

regn7075

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for regn7075

Regn7075 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating regn7075, 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for regn7075 clinical trials.

Breast carcinoma, colorectal carcinoma, and malignant solid tumor are the most common diseases being investigated in regn7075 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Regn7075
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating regn7075 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
regn 7075, regn-7075
Drug Target(s) [2]:
CD28, EGFR

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.